NCT07787156 Reach and Engagement of GENetic Education, Risk Assessment, and TEsting Feasibility Trial
| NCT ID | NCT07787156 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Brigham and Women's Hospital |
| Condition | Pancreatic Ductal Adenocarcinoma (PDAC) |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2026-10-15 |
| Primary Completion | 2028-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2026-10-15 with a primary completion date of 2028-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will test a remote approach to help people who may be at higher risk for pancreatic cancer learn about and decide whether to get genetic testing and a blood test that looks for signs of several cancers (MCED testing). The study is focused on Black, Latino/a, and Medicaid-enrolled individuals who may have had less access to cancer genetics and early detection services. About 80 participants, who reside in Massachusetts, will be assigned by chance to receive either online education alone or online education plus a phone call with a trained educator from the Pancreatic Cancer Action Network (PanCAN). After the education, participants can choose whether or not to have genetic testing and/or MCED testing. The main goal is to learn whether this approach is practical to carry out, acceptable to participants, and delivered as planned. Participants will complete 3 surveys during study participation.
Eligibility Criteria
Inclusion Criteria: * Aged 50 years or older OR 10 years younger than the earliest PDAC diagnosis in a family member * Current Medicaid enrollment and/or Black and/or Latino/a * Willingness to travel to Dana-Farber Cancer Institute in Boston, MA, for diagnostic testing if MCED screening test indicates possible malignancy * Living in the state of Massachusetts * No prior multi-gene panel genetic testing related to PDAC genetic risk * Internet access to complete study surveys * English speaking * Willing to complete study surveys * At least one first-degree relative with a PDAC diagnosis by participant report OR Any blood relative with a known pathogenic or likely pathogenic variant in a cancer susceptibility gene related to PDAC by participant report (e.g. ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2, STK11, or TP53) Exclusion Criteria: * Less than age 50 years or age not within 10 years of the earliest PDAC diagnosis in their family * Cancer diagnosis in the last 3 years (excluding non-melanoma skin cancers) * Currently pregnant * Insurance other than Medicaid or race/ethnicity other than Black or Latino/a * Prior genetic testing related to PDAC genetic risk * Genetic counseling in the last 3 years * Living in a state other than Massachusetts * Language other than English * Three members of the same family already enrolled in the study
Contact & Investigator
Nicolette J Rodriguez, MD, MPH
PRINCIPAL INVESTIGATOR
Brigham and Women's Hospital
Frequently Asked Questions
Who can join the NCT07787156 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pancreatic Ductal Adenocarcinoma (PDAC). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07787156 currently recruiting?
Yes, NCT07787156 is actively recruiting participants. Contact the research team at tial_kauffman@dfci.harvard.edu for enrollment information.
Where is the NCT07787156 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT07787156 clinical trial?
NCT07787156 is sponsored by Brigham and Women's Hospital. The principal investigator is Nicolette J Rodriguez, MD, MPH at Brigham and Women's Hospital. The trial plans to enroll 80 participants.